DE68915291T2 - Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz. - Google Patents
Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz.Info
- Publication number
- DE68915291T2 DE68915291T2 DE68915291T DE68915291T DE68915291T2 DE 68915291 T2 DE68915291 T2 DE 68915291T2 DE 68915291 T DE68915291 T DE 68915291T DE 68915291 T DE68915291 T DE 68915291T DE 68915291 T2 DE68915291 T2 DE 68915291T2
- Authority
- DE
- Germany
- Prior art keywords
- membrane
- active substance
- physiologically active
- cavity
- body according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013543 active substance Substances 0.000 title claims description 65
- 239000012528 membrane Substances 0.000 claims description 103
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 44
- 230000002209 hydrophobic effect Effects 0.000 claims description 44
- 229960002715 nicotine Drugs 0.000 claims description 44
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 44
- 239000012982 microporous membrane Substances 0.000 claims description 19
- 229920000609 methyl cellulose Polymers 0.000 claims description 18
- 239000001923 methylcellulose Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical group O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 239000010677 tea tree oil Substances 0.000 claims description 9
- 229940111630 tea tree oil Drugs 0.000 claims description 9
- 229960004605 timolol Drugs 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 230000009969 flowable effect Effects 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229960002428 fentanyl Drugs 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002896 clonidine Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- 229960002646 scopolamine Drugs 0.000 claims description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 2
- 239000011344 liquid material Substances 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 239000002650 laminated plastic Substances 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 description 91
- 239000000463 material Substances 0.000 description 27
- 239000002904 solvent Substances 0.000 description 26
- -1 reserpine Chemical compound 0.000 description 19
- 239000004480 active ingredient Substances 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 239000010410 layer Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000004743 Polypropylene Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229920001155 polypropylene Polymers 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 7
- 229920000573 polyethylene Polymers 0.000 description 7
- 239000012790 adhesive layer Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 229920005573 silicon-containing polymer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000011505 plaster Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 2
- 229960001383 methylscopolamine Drugs 0.000 description 2
- 239000012229 microporous material Substances 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 230000036555 skin type Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PSQYTAPXSHCGMF-BQYQJAHWSA-N β-ionone Chemical compound CC(=O)\C=C\C1=C(C)CCCC1(C)C PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 2
- SFEOKXHPFMOVRM-UHFFFAOYSA-N (+)-(S)-gamma-ionone Natural products CC(=O)C=CC1C(=C)CCCC1(C)C SFEOKXHPFMOVRM-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VTHUYJIXSMGYOQ-KOORYGTMSA-N 17-hydroxyprogesterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VTHUYJIXSMGYOQ-KOORYGTMSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DRLLEHPFGRESBT-UHFFFAOYSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl acetate;hydron;dichloride Chemical compound Cl.Cl.C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DRLLEHPFGRESBT-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 150000005011 4-aminoquinolines Chemical class 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-UWKORSIYSA-N 6-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1C(C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-UWKORSIYSA-N 0.000 description 1
- 150000005012 8-aminoquinolines Chemical class 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- TUQLBJAHRWROHB-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)butan-2-amine Chemical compound CC(O)=O.C1=CC=C2C(CC(N)CC)=CNC2=C1 TUQLBJAHRWROHB-UHFFFAOYSA-N 0.000 description 1
- NMZSAMXFINECBQ-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)propan-2-amine Chemical compound CC([O-])=O.C1=CC=C2C(CC([NH3+])C)=CNC2=C1 NMZSAMXFINECBQ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 229960001658 carbromal Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000002651 laminated plastic film Substances 0.000 description 1
- 239000012705 liquid precursor Substances 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960003141 secobarbital sodium Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- AXXJTNXVUHVOJW-UHFFFAOYSA-M sodium;5-pentan-2-yl-5-prop-2-enylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O AXXJTNXVUHVOJW-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888804164A GB8804164D0 (en) | 1988-02-23 | 1988-02-23 | Bandage for administering physiologically active compound |
| PCT/GB1989/000185 WO1989007959A1 (en) | 1988-02-23 | 1989-02-23 | Occlusive body for administering a physiologically active substance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68915291D1 DE68915291D1 (de) | 1994-06-16 |
| DE68915291T2 true DE68915291T2 (de) | 1994-09-01 |
Family
ID=10632193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE68915291T Expired - Fee Related DE68915291T2 (de) | 1988-02-23 | 1989-02-23 | Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5254346A (https=) |
| EP (2) | EP0336543A1 (https=) |
| JP (1) | JP2716231B2 (https=) |
| KR (1) | KR970009723B1 (https=) |
| AU (1) | AU618085B2 (https=) |
| DE (1) | DE68915291T2 (https=) |
| ES (1) | ES2052071T3 (https=) |
| GB (1) | GB8804164D0 (https=) |
| IN (1) | IN172748B (https=) |
| WO (1) | WO1989007959A1 (https=) |
| ZA (1) | ZA891403B (https=) |
Families Citing this family (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
| JPH02149514A (ja) * | 1988-04-06 | 1990-06-08 | Nitto Denko Corp | 医薬部材 |
| EP0470007B1 (en) * | 1990-08-03 | 1995-03-15 | Terumo Kabushiki Kaisha | Wound-covering materials |
| GB9021674D0 (en) * | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
| US5240917A (en) * | 1991-04-03 | 1993-08-31 | Keimowitz Rudolph M | Suppression of thromboxane levels by percutaneous administration of aspirin |
| US5123900A (en) * | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
| CH686816A5 (de) * | 1992-02-04 | 1996-07-15 | Asulab Ag | Einrichtung zur Abgabe eines Arzneimittels. |
| US6071896A (en) * | 1992-06-16 | 2000-06-06 | Gundersen Clinic, Ltd. | Suppression of thromboxane levels by percutaneous administration of aspirin |
| DE4236886C2 (de) * | 1992-10-31 | 1997-11-20 | Klocke Verpackungs Service | Behälter zur Aufnahme von aromatischen Substanzen |
| JPH08503465A (ja) * | 1992-11-09 | 1996-04-16 | ファーメトリックス コーポレイション | ケトロラックの経皮デリバリー |
| FR2709670B1 (fr) * | 1993-09-10 | 1995-10-20 | Asulab Sa | Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse. |
| JP3021661B2 (ja) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| DE4423850A1 (de) * | 1994-07-07 | 1996-01-11 | Labtec Gmbh | Transdermales therapeutisches System zur Applikation von Naloxon |
| DE19517145C2 (de) * | 1995-05-10 | 2000-02-24 | Hexal Pharmaforschung Gmbh | Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron |
| US5730721A (en) | 1996-01-25 | 1998-03-24 | Vesture Corporation | Medical applicator and method |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US5800832A (en) * | 1996-10-18 | 1998-09-01 | Virotex Corporation | Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces |
| US6119036A (en) * | 1997-03-26 | 2000-09-12 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
| US5919476A (en) * | 1997-09-29 | 1999-07-06 | Pmt Corporation | Reinforced gel sheeting for scar treatment |
| DE19743484C1 (de) * | 1997-10-01 | 1999-01-28 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems |
| US7011843B2 (en) | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
| US20050048102A1 (en) * | 1997-10-16 | 2005-03-03 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| US6087341A (en) * | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
| WO1999061007A1 (de) * | 1998-05-22 | 1999-12-02 | Novosis Pharma Ag | Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme |
| DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| DE19934523A1 (de) * | 1999-07-22 | 2001-01-25 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich |
| US7713546B1 (en) | 2001-04-03 | 2010-05-11 | Soft Gel Technologies, Inc. | Corosolic acid formulation and its application for weight-loss management and blood sugar balance |
| USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
| US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
| EP1390084B1 (en) | 2001-05-01 | 2011-03-23 | A.V. Topchiev Institute of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
| ES2331302T3 (es) | 2001-05-01 | 2009-12-29 | A.V. Topchiev Institute Of Petrochemical Synthesis | Composiciones de hidrogel. |
| US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
| US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
| US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| CA2492654A1 (en) * | 2002-07-16 | 2004-01-22 | University Of South Florida | Human immunosuppressive protein |
| EP2316459B1 (en) | 2002-07-29 | 2013-11-06 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases |
| JP2006510618A (ja) | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス，インコーポレーテッド | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
| CA2453013C (en) * | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
| CA2522184A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Of New York | Desmoglein 4 is a novel gene involved in hair growth |
| EP1648363B1 (en) | 2003-07-03 | 2019-03-06 | Corium International, Inc. | Wound dressing, ingredient delivery device and iv hold-down, and method relating to same |
| ATE506953T1 (de) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| AU2004269986A1 (en) * | 2003-09-08 | 2005-03-17 | Pfizer Consumer Healthcare Health Ab | Nicotine formulations and use thereof |
| RU2380092C2 (ru) | 2004-01-30 | 2010-01-27 | Кориум Интернэшнл, Инк. | Быстро растворяющаяся пленка для доставки активного агента |
| US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
| EP1747022A4 (en) * | 2004-04-23 | 2010-03-31 | Univ Columbia | INHIBITION OF HAIRLESS PROTEIN MRNA |
| US20050249791A1 (en) * | 2004-05-07 | 2005-11-10 | 3M Innovative Properties Company | Antimicrobial articles |
| GB2414461B (en) * | 2004-05-24 | 2007-09-12 | Mark Rupert Tucker | Form-fill-seal process |
| EP1791575B1 (en) | 2004-08-05 | 2014-10-08 | Corium International, Inc. | Adhesive composition |
| US20060051435A1 (en) * | 2004-08-19 | 2006-03-09 | Udell Ronald G | Nutritional supplement for body fat reduction |
| US20060079514A1 (en) * | 2004-10-13 | 2006-04-13 | Victory Pharma Incorporated | Methods and compositions including methscopolamine bromide |
| US20060079513A1 (en) * | 2004-10-13 | 2006-04-13 | Preston David M | Methods and compositions including methscopolamine nitrate |
| SI1814531T1 (sl) | 2004-10-21 | 2010-10-29 | Durect Corp | Transdermalni dostavni sistem |
| US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
| GB2421431B (en) * | 2004-12-24 | 2007-10-10 | Aquasol Ltd | Dosing systems |
| US20070104805A1 (en) * | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
| AT502717A1 (de) * | 2005-11-09 | 2007-05-15 | Omnica Gmbh | Pharmazeutische verwendung einer verbindung |
| GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
| JP2009519246A (ja) * | 2005-12-08 | 2009-05-14 | フェルティン ファルマ | 経皮タバコアルカロイドパッチ |
| WO2007065428A1 (en) * | 2005-12-08 | 2007-06-14 | Fertin Pharma | Low flexural strength transdermal tobacco alkaloid patch |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| US9109204B2 (en) * | 2006-02-28 | 2015-08-18 | The Trustees Of Columbia University In The City Of New York | Methods for compact aggregation of dermal cells |
| AT503329A1 (de) * | 2006-03-02 | 2007-09-15 | Omnica Gmbh | Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält |
| AT503521A1 (de) * | 2006-05-05 | 2007-11-15 | Omnica Gmbh | Verwendung eines extraktes von kiwi-frucht |
| US8278358B2 (en) * | 2006-07-06 | 2012-10-02 | Omnica Gmbh | Lipoic acid derivatives |
| DK2054031T3 (en) | 2006-07-21 | 2016-05-17 | Biodelivery Sciences Int Inc | Transmucosal delivery devices with improved uptake |
| JP2008044926A (ja) * | 2006-08-14 | 2008-02-28 | Trustees Of Columbia Univ In The City Of New York | Ｗｎｔ信号伝達に関係した分泌タンパク質 |
| JP5161233B2 (ja) | 2006-10-19 | 2013-03-13 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体 |
| ATE540041T1 (de) | 2006-11-21 | 2012-01-15 | Rigel Pharmaceuticals Inc | Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon |
| US7820207B2 (en) * | 2007-03-15 | 2010-10-26 | Omnica Gmbh | Stabilized anthocyanin compositions |
| US8623429B2 (en) | 2007-03-15 | 2014-01-07 | Omnica Gmbh | Stabilized anthocyanin compositions |
| US20080293644A1 (en) * | 2007-04-27 | 2008-11-27 | Thomas Eidenberger | Guava extract |
| WO2008145119A1 (en) * | 2007-05-31 | 2008-12-04 | Fertin Pharma A/S | Transdermal tobacco alkaloid reservoir patch |
| US8034983B2 (en) * | 2007-06-06 | 2011-10-11 | Multi-Tech Specialty Chemicals, Co., Ltd. | Process for the preparation of xanthophyll crystals |
| DK2176208T3 (en) | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
| JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ，インク． | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
| WO2009089380A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of Columbia University In The City Of New York | Methods for p2ry5 mediated regulation of hair growth and mutants thereof |
| US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
| US20090270398A1 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
| US8236838B2 (en) * | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090264433A1 (en) * | 2008-04-21 | 2009-10-22 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Triazine Derivatives |
| WO2009131957A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| RS54413B1 (sr) * | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| JP2012503005A (ja) * | 2008-09-19 | 2012-02-02 | インスティテュート フォア ワンワールド ヘルス | イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。 |
| AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| JP5815411B2 (ja) | 2008-12-30 | 2015-11-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ピリミジンジアミンキナーゼ阻害剤 |
| WO2010083035A2 (en) | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| BRPI1006942A2 (pt) | 2009-01-23 | 2016-04-12 | Rigel Pharmaceuticals Inc | composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto |
| EP2393488B1 (en) | 2009-02-06 | 2019-06-19 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| US8511216B2 (en) * | 2009-03-30 | 2013-08-20 | Kanzaki Kokyukoki Mfg. Co., Ltd. | Hydraulic actuator unit |
| US8343976B2 (en) * | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| AU2010270797B2 (en) | 2009-07-08 | 2015-03-19 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
| US20110034415A1 (en) | 2009-07-20 | 2011-02-10 | Thomas Eidenberger | Walnut extracts for nutraceutical applications |
| US20110038904A1 (en) * | 2009-08-17 | 2011-02-17 | Silipos Inc. | Gel Product |
| FR2955324A1 (fr) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
| WO2011053468A1 (en) | 2009-10-30 | 2011-05-05 | Sanofi-Aventis | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
| US20110144200A1 (en) | 2009-12-14 | 2011-06-16 | Thomas Eidenberger | Combination of carotenoids and epi-lutein |
| CA2785439A1 (en) | 2009-12-23 | 2011-06-30 | Sanofi | [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
| RS53456B (sr) | 2009-12-23 | 2014-12-31 | Sanofi | Prolekovi [4[4-(5-aminometil-2-fluor-fenil)-piperidin-1-il]-(1h-pirolo-piridin-il)-metanona i njihova sinteza |
| WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
| US20110288093A1 (en) | 2010-04-20 | 2011-11-24 | Institute For Oneworld Health | Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives |
| CN103096889A (zh) | 2010-04-20 | 2013-05-08 | 寰宇一家健康研究所 | 包含1,3,4-噁二唑衍生物的化合物、组合物和方法 |
| AU2011242562B2 (en) | 2010-04-24 | 2016-10-13 | Mycovia Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| JP6073221B2 (ja) | 2010-07-28 | 2017-02-01 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| US9056855B2 (en) | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2012061537A2 (en) | 2010-11-02 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| KR101848077B1 (ko) | 2010-11-13 | 2018-04-11 | 이노크린 파마슈티컬즈, 인크. | 금속효소 억제제 화합물 |
| CN103328452A (zh) | 2010-12-13 | 2013-09-25 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
| CA2820425A1 (en) | 2010-12-20 | 2012-06-28 | Colgate-Palmolive Company | Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier |
| CA2828360A1 (en) | 2011-02-25 | 2012-08-30 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Chrysophaentin analogs that inhibit ftsz protein |
| CN103501821A (zh) | 2011-03-08 | 2014-01-08 | 艾克塞斯制药公司 | 用于递送活性剂穿过生物膜的靶向纳米载体系统 |
| KR20140040235A (ko) | 2011-06-19 | 2014-04-02 | 비아멧 파마슈티컬즈, 인코포레이티드 | 금속효소 억제제 화합물 |
| AU2012273100B2 (en) | 2011-06-19 | 2017-05-25 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| US8940735B2 (en) | 2011-06-23 | 2015-01-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2013019169A1 (en) | 2011-08-01 | 2013-02-07 | Institute For Oneworld Health | Phosphate prodrugs |
| AU2012296346A1 (en) | 2011-08-18 | 2014-04-03 | Biodelivery Sciences International, Inc. | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| CN103930165B (zh) | 2011-09-02 | 2018-05-25 | 纽约市哥伦比亚大学理事会 | 用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂 |
| IN2014MN01378A (https=) | 2011-12-11 | 2015-07-03 | Viamet Pharmaceuticals Inc | |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| WO2013109998A1 (en) | 2012-01-20 | 2013-07-25 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CA2865504A1 (en) | 2012-03-23 | 2013-09-26 | Oxigene, Inc. | Compositions and methods for inhibition of cathepsins |
| DK2830662T3 (da) | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| JP2016506930A (ja) | 2013-01-25 | 2016-03-07 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患を処置するための化合物および方法 |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| US20150157509A1 (en) * | 2013-12-11 | 2015-06-11 | Oscar Polk Atkinson | Occlusive skin covering |
| US20150174386A1 (en) * | 2013-12-19 | 2015-06-25 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
| MX2016011517A (es) | 2014-03-07 | 2017-04-13 | Univ Arizona | Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico. |
| WO2015143184A1 (en) | 2014-03-19 | 2015-09-24 | Viamet Pharmaceuticals, Inc. | Antifungal compound process |
| EP3925979A3 (en) | 2014-12-23 | 2022-03-23 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
| KR102603277B1 (ko) | 2015-03-19 | 2023-11-17 | 마이코비아 파마슈티컬즈, 인코포레이티드 | 항진균성 화합물 및 이의 제조 방법 |
| DK3331879T3 (da) | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne |
| CN108289457B (zh) | 2015-09-18 | 2021-08-06 | 迈科维亚医药公司 | 抗真菌化合物制备方法 |
| US10188750B1 (en) | 2015-10-23 | 2019-01-29 | University Of South Florida | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
| EA038421B1 (ru) | 2015-12-30 | 2021-08-26 | ВиПиЭс-3, ИНК. | Соединения, ингибирующие металлоферменты |
| AU2017229125B2 (en) | 2016-03-08 | 2021-07-29 | Living Proof, Inc. | Long lasting cosmetic compositions |
| WO2017210611A1 (en) | 2016-06-03 | 2017-12-07 | Biovinc, Llc. | Bisphosphonate quinolone conjugates and uses thereof |
| EP3475263B1 (en) | 2016-06-27 | 2022-12-28 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors |
| ES2985944T3 (es) | 2016-06-29 | 2024-11-07 | Halo Life Science Llc | Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor |
| JP7170634B2 (ja) | 2016-10-26 | 2022-11-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法 |
| ES2946001T3 (es) | 2016-10-26 | 2023-07-11 | Rigel Pharmaceuticals Inc | Compuestos de pirazol amida como inhibidores de IRAK |
| JP7227157B2 (ja) | 2016-12-29 | 2023-02-21 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 金属酵素阻害剤化合物 |
| EP3562306B1 (en) | 2016-12-29 | 2025-02-26 | Ji Xing Pharmaceuticals Hong Kong Limited | Metalloenzyme inhibitor compounds |
| GB201708579D0 (en) * | 2017-05-30 | 2017-07-12 | Univ Of Wolverhampton Science Park Ltd | Wound dressing |
| CA3068305A1 (en) | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| GB2561262B (en) * | 2017-07-13 | 2019-03-20 | Dentmed Ltd | A targeted drug delivery pad |
| EP3681921A2 (en) | 2017-09-13 | 2020-07-22 | Living Proof, Inc. | Color protectant compositions |
| AU2018333932B2 (en) | 2017-09-13 | 2024-05-02 | Living Proof, Inc. | Long lasting cosmetic compositions |
| CN111356501A (zh) | 2017-11-20 | 2020-06-30 | 生活实验公司 | 实现持久化妆品性能的属性 |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| BR112020021902B1 (pt) | 2018-04-27 | 2024-02-20 | Living Proof, Inc | Composições cosméticas de poliuretano-ureia para tratamento capilar, método de preservação da ondulação no cabelo humano e os usos de poliuretano-ureia |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| CA3105829A1 (en) | 2018-07-09 | 2020-01-16 | Biovinc, Llc. | Bisphosphonate quinolone conjugates and uses thereof |
| WO2020092845A1 (en) | 2018-11-01 | 2020-05-07 | Rigel Pharmaceuticals, Inc. | Method and composition embodiments for treating acute myeloid leukemia |
| JP2022516969A (ja) | 2019-01-08 | 2022-03-03 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 金属酵素阻害剤化合物 |
| US11090346B2 (en) | 2019-05-28 | 2021-08-17 | Inbold Inc. | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery |
| WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
| MX2022001596A (es) | 2019-08-08 | 2022-03-11 | Rigel Pharmaceuticals Inc | Compuestos y metodos para tratar sindrome de liberacion de citocinas. |
| EP4013420B1 (en) | 2019-08-14 | 2023-11-01 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
| PE20220970A1 (es) | 2019-08-30 | 2022-06-10 | Rigel Pharmaceuticals Inc | Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| SI4055021T1 (sl) | 2019-11-07 | 2026-02-27 | Rigel Pharmaceuticals, Inc. | Heterociklične spojine, ki inhibirajo rip1 |
| US12357623B2 (en) | 2021-03-03 | 2025-07-15 | Rigel Pharmaceuticals, Inc. | Method for treating a disease or condition using a pyrazole compound or formulation thereof |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| WO2023136749A1 (ru) * | 2022-01-11 | 2023-07-20 | Павел Владимирович КОРЧАГИН | Система и способ обеспечения безопасности для держателей банковских карт |
| IL315677A (en) | 2022-03-23 | 2024-11-01 | Rigel Pharmaceuticals Inc | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
| WO2023192479A1 (en) | 2022-03-31 | 2023-10-05 | Rigel Pharmaceuticals, Inc. | Tricyclic irak inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| AU1147476A (en) * | 1975-03-19 | 1977-09-01 | Procter & Gamble | Controlled release article |
| US4725272A (en) * | 1981-06-29 | 1988-02-16 | Alza Corporation | Novel bandage for administering beneficial drug |
| DE3586713T2 (de) * | 1984-11-15 | 1993-05-13 | Hercon Lab | Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen. |
| US4752478A (en) * | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
| EP0186019B1 (de) * | 1984-12-22 | 1993-10-06 | Schwarz Pharma Ag | Wirkstoffpflaster |
| US4597961A (en) * | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| GB8512358D0 (en) * | 1985-05-16 | 1985-06-19 | Euro Celtique Sa | Transdermal delivery system |
-
1988
- 1988-02-23 GB GB888804164A patent/GB8804164D0/en active Pending
-
1989
- 1989-02-23 EP EP89301777A patent/EP0336543A1/en active Pending
- 1989-02-23 ES ES89903777T patent/ES2052071T3/es not_active Expired - Lifetime
- 1989-02-23 AU AU32895/89A patent/AU618085B2/en not_active Ceased
- 1989-02-23 ZA ZA891403A patent/ZA891403B/xx unknown
- 1989-02-23 DE DE68915291T patent/DE68915291T2/de not_active Expired - Fee Related
- 1989-02-23 IN IN173DE1989 patent/IN172748B/en unknown
- 1989-02-23 JP JP1503462A patent/JP2716231B2/ja not_active Expired - Fee Related
- 1989-02-23 WO PCT/GB1989/000185 patent/WO1989007959A1/en not_active Ceased
- 1989-02-23 EP EP89903777A patent/EP0508979B1/en not_active Expired - Lifetime
- 1989-02-23 US US07/555,463 patent/US5254346A/en not_active Expired - Lifetime
- 1989-02-23 KR KR1019890701941A patent/KR970009723B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03503636A (ja) | 1991-08-15 |
| AU618085B2 (en) | 1991-12-12 |
| KR970009723B1 (ko) | 1997-06-17 |
| GB8804164D0 (en) | 1988-03-23 |
| EP0508979A1 (en) | 1992-10-21 |
| EP0336543A1 (en) | 1989-10-11 |
| KR900700153A (ko) | 1990-08-11 |
| WO1989007959A1 (en) | 1989-09-08 |
| ES2052071T3 (es) | 1994-07-01 |
| ZA891403B (en) | 1989-11-29 |
| US5254346A (en) | 1993-10-19 |
| IN172748B (https=) | 1993-11-20 |
| DE68915291D1 (de) | 1994-06-16 |
| EP0508979B1 (en) | 1994-05-11 |
| AU3289589A (en) | 1989-09-22 |
| JP2716231B2 (ja) | 1998-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68915291T2 (de) | Verschlusskörpr zur verabreichung einer physiologisch aktiven substanz. | |
| DE69130232T2 (de) | Transdermale verhütungsmittelformulierung, verfahren und vorrichtung | |
| DE68926122T2 (de) | Transdermale estrogen/progestin-dosiereinheit und system. | |
| DE3205258C2 (https=) | ||
| DE3881340T2 (de) | Vorrichtung zur transdermalen applikation von medikamenten. | |
| DE69615399T2 (de) | Triacetin zur erhöhung der transdermalen penetration | |
| DE3526339C2 (https=) | ||
| DE69524436T2 (de) | Verbesserte transdermale vorrichtung mit verringerter delaminierung | |
| DE69422925T2 (de) | Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten | |
| DE69430917T2 (de) | 3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT | |
| DE60021099T2 (de) | Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung | |
| EP0261402B1 (de) | Transdermales therapeutisches System, seine Verwendung und Verfahren zu seiner Herstellung | |
| DE3642931C2 (de) | Mehrfach Unterteilte Transdermale und Dermale Pflaster | |
| JP3916664B2 (ja) | グリセロールモノラウレートとラウリルアセテートとを含む皮膚透過増強剤組成物 | |
| DE3844247C2 (https=) | ||
| DE3751447T2 (de) | Transdermale östrogen-/progestin-Einheitsdosis, Kit zur Fertilitätskontrolle enthaltend diese Einheitsdosis. | |
| EP0341202B1 (de) | Transdermale Monolithsysteme | |
| DE2604718C2 (de) | Therapeutische Vorrichtung zur Verabreichung von Skopolaminbase und Verfahren zu deren Herstellung | |
| CH674618A5 (https=) | ||
| DE3876756T2 (de) | Vorrichtung zur gesteuerten freigabe und verabreichung von wirkstoffen an tierisches gewebe. | |
| EP0273004B1 (de) | Benutzer-aktivierte Therapeutische Systeme | |
| DE3714140C2 (https=) | ||
| DE69923348T9 (de) | Transdermales arzneistoffverabreichungssystem | |
| EP1191927A1 (de) | Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln | |
| DE3905051A1 (de) | Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (i) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: TUCKER, CHRISTOBEL CAROLINE, STOW-ON-THE-WOLD, GLO Owner name: TUCKER, MARK RUPERT, CHIPPING NORTEN, OXON, GB |
|
| 8381 | Inventor (new situation) |
Inventor name: TUCKER, JOHN MARK, STOW-ON-THE-WOLD, GLOUCESTER, G Inventor name: TUCKER, MARK RUPERT, ST.BRELADE, JERSEY, GB |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: STOWIC RESOURCES LTD., STOW-ON-THE-WOLD, GLOUCESTE |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: UNITED PHARMACEUTICAL MANUFACTURING CO. LTD., AMMA |
|
| 8339 | Ceased/non-payment of the annual fee |